Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.
2.

Absence of TXNIP in Humans Leads to Lactic Acidosis and Low Serum Methionine Linked to Deficient Respiration on Pyruvate.

Katsu-Jiménez Y, Vázquez-Calvo C, Maffezzini C, Halldin M, Peng X, Freyer C, Wredenberg A, Giménez-Cassina A, Wedell A, Arnér ESJ.

Diabetes. 2019 Apr;68(4):709-723. doi: 10.2337/db18-0557. Epub 2019 Feb 12.

PMID:
30755400
3.

GH Dose Reduction Maintains Normal Prepubertal Height Velocity After Initial Catch-Up Growth in Short Children.

Decker R, Albertsson-Wikland K, Kriström B, Halldin M, Gustafsson J, Nilsson NÖ, Dahlgren J.

J Clin Endocrinol Metab. 2019 Mar 1;104(3):835-844. doi: 10.1210/jc.2018-01006.

PMID:
30339244
4.

High DPP-4 Concentrations in Adolescents Are Associated With Low Intact GLP-1.

Stenlid R, Manell H, Halldin M, Kullberg J, Ahlström H, Manukyan L, Weghuber D, Paulmichl K, Zsoldos F, Bergsten P, Forslund A.

J Clin Endocrinol Metab. 2018 Aug 1;103(8):2958-2966. doi: 10.1210/jc.2018-00194.

PMID:
29850829
5.

Clinical testing of three novel transient receptor potential cation channel subfamily V member 1 antagonists in a pharmacodynamic intradermal capsaicin model.

Sjögren E, Kullenberg T, Jonzon B, Segerdahl M, Stålberg O, Halldin MM, Sundgren-Andersson AK.

Eur J Pain. 2018 Aug;22(7):1214-1228. doi: 10.1002/ejp.1209. Epub 2018 Apr 10.

PMID:
29504187
6.

Preclinical characterization of three transient receptor potential vanilloid receptor 1 antagonists for early use in human intradermal microdose analgesic studies.

Sjögren E, Halldin MM, Stålberg O, Sundgren-Andersson AK.

Eur J Pain. 2018 May;22(5):889-903. doi: 10.1002/ejp.1175. Epub 2018 Jan 26.

PMID:
29377430
7.

Most patients with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency develop pathological or subnormal retinal function.

Fahnehjelm KT, Liu Y, Olsson D, Amrén U, Haglind CB, Holmström G, Halldin M, Andreasson S, Nordenström A.

Acta Paediatr. 2016 Dec;105(12):1451-1460. doi: 10.1111/apa.13536. Epub 2016 Sep 15.

PMID:
27461099
8.

Assessment of Free Drug Concentration in Cyclodextrin Formulations Is Essential to Determine Drug Potency in Functional In Vitro Assays.

Sjögren E, Andersson S, Sundgren-Andersson AK, Halldin MM, Stålberg O.

J Pharm Sci. 2016 Sep;105(9):2913-2920. doi: 10.1016/j.xphs.2016.04.030. Epub 2016 Jul 16.

PMID:
27431012
9.

The metabolic syndrome and ECG detected left ventricular hypertrophy--influences from IGF-1 and IGF-binding protein-1.

Halldin M, Brismar K, Fahlstadius P, Vikström M, de Faire U, Hellénius ML.

PLoS One. 2014 Dec 2;9(12):e108872. doi: 10.1371/journal.pone.0108872. eCollection 2014.

10.

The battle of Alzheimer's Disease - the beginning of the future Unleashing the potential of academic discoveries.

Lundkvist J, Halldin MM, Sandin J, Nordvall G, Forsell P, Svensson S, Jansson L, Johansson G, Winblad B, Ekstrand J.

Front Pharmacol. 2014 May 9;5:102. doi: 10.3389/fphar.2014.00102. eCollection 2014.

11.

Pragmatic approaches to determine the exposures of drug metabolites in preclinical and clinical subjects in the MIST evaluation of the clinical development phase.

Haglund J, Halldin MM, Brunnström A, Eklund G, Kautiainen A, Sandholm A, Iverson SL.

Chem Res Toxicol. 2014 Apr 21;27(4):601-10. doi: 10.1021/tx400449z. Epub 2014 Mar 24.

PMID:
24593263
12.

The impact of the site of blood sampling on pharmacokinetic parameters following sublingual dosing to dogs.

Sohlberg E, Halldin MM, Annas A, Königsson K, Jansson B, Pehrson R, Borg N.

J Pharmacol Toxicol Methods. 2013 Jan-Feb;67(1):1-4. doi: 10.1016/j.vascn.2012.10.004. Epub 2012 Nov 5.

PMID:
23138149
13.

Functional changes in adipose tissue in a randomised controlled trial of physical activity.

Sjögren P, Sierra-Johnson J, Kallings LV, Cederholm T, Kolak M, Halldin M, Brismar K, de Faire U, Hellénius ML, Fisher RM.

Lipids Health Dis. 2012 Jun 21;11:80. doi: 10.1186/1476-511X-11-80.

14.

Decreased GH dose after the catch-up growth period maintains metabolic outcome in short prepubertal children with and without classic GH deficiency.

Decker R, Albertsson-Wikland K, Kriström B, Halldin M, Dahlgren J.

Clin Endocrinol (Oxf). 2012 Sep;77(3):407-15. doi: 10.1111/j.1365-2265.2012.04386.x.

PMID:
22417085
15.

The metabolic syndrome and left ventricular hypertrophy--the influence of gender and physical activity.

Halldin M, Fahlstadius P, de Faire U, Vikström M, Hellénius ML.

Blood Press. 2012 Jun;21(3):153-60. doi: 10.3109/08037051.2012.641267. Epub 2011 Dec 19.

PMID:
22181656
16.

Adenosine kinase deficiency disrupts the methionine cycle and causes hypermethioninemia, encephalopathy, and abnormal liver function.

Bjursell MK, Blom HJ, Cayuela JA, Engvall ML, Lesko N, Balasubramaniam S, Brandberg G, Halldin M, Falkenberg M, Jakobs C, Smith D, Struys E, von Döbeln U, Gustafsson CM, Lundeberg J, Wedell A.

Am J Hum Genet. 2011 Oct 7;89(4):507-15. doi: 10.1016/j.ajhg.2011.09.004. Epub 2011 Sep 28.

17.

Low levels of IgM antibodies to phosphorylcholine predict cardiovascular disease in 60-year old men: effects on uptake of oxidized LDL in macrophages as a potential mechanism.

de Faire U, Su J, Hua X, Frostegård A, Halldin M, Hellenius ML, Wikström M, Dahlbom I, Grönlund H, Frostegård J.

J Autoimmun. 2010 Mar;34(2):73-9. doi: 10.1016/j.jaut.2009.05.003. Epub 2009 Sep 2.

PMID:
19726160
18.

Is a unified definition of metabolic syndrome needed? Comparison of three definitions of metabolic syndrome in 60-year-old men and women.

Carlsson AC, Wändell PE, Halldin M, de Faire U, Hellénius ML.

Metab Syndr Relat Disord. 2009 Jun;7(3):231-41. doi: 10.1089/met.2008.0078.

PMID:
19284315
19.

Growth hormone (GH) dosing during catch-up growth guided by individual responsiveness decreases growth response variability in prepubertal children with GH deficiency or idiopathic short stature.

Kriström B, Aronson AS, Dahlgren J, Gustafsson J, Halldin M, Ivarsson SA, Nilsson NO, Svensson J, Tuvemo T, Albertsson-Wikland K.

J Clin Endocrinol Metab. 2009 Feb;94(2):483-90. doi: 10.1210/jc.2008-1503. Epub 2008 Nov 11.

PMID:
19001519
20.

Ocular characteristics in 10 children with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: a cross-sectional study with long-term follow-up.

Fahnehjelm KT, Holmström G, Ying L, Haglind CB, Nordenström A, Halldin M, Alm J, Nemeth A, von Döbeln U.

Acta Ophthalmol. 2008 May;86(3):329-37. Epub 2007 Dec 19. Erratum in: Acta Ophthalmol. 2008 Jun;86(4):466.

21.

The metabolic syndrome: prevalence and association to leisure-time and work-related physical activity in 60-year-old men and women.

Halldin M, Rosell M, de Faire U, Hellénius ML.

Nutr Metab Cardiovasc Dis. 2007 Jun;17(5):349-57. Epub 2006 Mar 31.

PMID:
17562572
22.

A trial with N-carbamylglutamate may not detect all patients with NAGS deficiency and neonatal onset.

Nordenström A, Halldin M, Hallberg B, Alm J.

J Inherit Metab Dis. 2007 Jun;30(3):400. Epub 2007 May 9.

PMID:
17510757
23.

Increased lipolysis in LCHAD deficiency.

Halldin MU, Forslund A, von Döbeln U, Eklund C, Gustafsson J.

J Inherit Metab Dis. 2007 Feb;30(1):39-46. Epub 2006 Dec 9.

PMID:
17160563
24.

[Reply from the SBU about salt and high blood pressure: More controlled long-term trials are required].

Halldin M, Hjemdahl P, de Faire U, Lindholm LH, Samuelsson O.

Lakartidningen. 2004 Dec 23;101(51-52):4257. Swedish. No abstract available.

PMID:
15658599
25.

Profound changes in the GH-IGF-I system in adolescent girls with IDDM: can IGFBP1 be used to reflect overall glucose regulation?

Halldin MU, Hagenäs L, Tuvemo T, Gustafsson J.

Pediatr Diabetes. 2000 Sep;1(3):121-30.

PMID:
15016222
26.

[Evidence-based medicine for students at the Danderyd hospital and the Karolinska hospital. A new appreciated element in medical education].

Näslund E, Halldin M, Sahlin S, Svenberg T.

Lakartidningen. 2003 Mar 6;100(10):854-6. Swedish. No abstract available.

PMID:
12680023
27.

[Physical activity reduces blood pressure].

Halldin M.

Lakartidningen. 2002 Oct 31;99(44):4379. Swedish. No abstract available.

PMID:
12469585
28.

Insulin sensitivity and lipolysis in adolescent girls with poorly controlled type 1 diabetes: effect of anticholinergic treatment.

Halldin MU, Brismar K, Tuvemo T, Gustafsson J.

Clin Endocrinol (Oxf). 2002 Dec;57(6):735-43.

PMID:
12460323
29.

Involvement of liver carboxylesterases in the in vitro metabolism of lidocaine.

Alexson SE, Diczfalusy M, Halldin M, Swedmark S.

Drug Metab Dispos. 2002 Jun;30(6):643-7.

PMID:
12019189
30.

Anticholinergic treatment improves glycaemic control in adolescent girls with insulin-dependent diabetes mellitus.

Halldin MU, Aman J, Brismar K, Jones I, Tuvemo T, Gustafsson J.

Acta Paediatr. 2001 Apr;90(4):393-9.

PMID:
11332929
31.

Metabolism of sameridine to monocarboxylated products by hepatocytes isolated from the male rat.

Sohlenius-Sternbeck AK, Chelpin HV, Orzechowski A, Halldin MM.

Drug Metab Dispos. 2000 Jun;28(6):695-700.

PMID:
10820143
32.

Liquid chromatographic bioanalytical determination of ropivacaine, bupivacaine and major metabolites.

Arvidsson T, Askemark Y, Halldin MM.

Biomed Chromatogr. 1999 Jun;13(4):286-92.

PMID:
10416062
33.

Is growth hormone hypersecretion in diabetic adolescent girls also a daytime problem?

Halldin MU, Tylleskär K, Hagenäs L, Tuvemo T, Gustafsson J.

Clin Endocrinol (Oxf). 1998 Jun;48(6):785-94.

PMID:
9713569
34.

[CVK (Center for Communication Science)--a multidisciplinary way for hearing improvement].

Halldin M, Lundborg T.

Lakartidningen. 1998 Jan 21;95(4):257. Swedish. No abstract available.

PMID:
9469953
35.

Comparative local anesthetic efficacy and pharmacokinetics of epidurally administered ropivacaine and bupivacaine in the sheep.

Feldman HS, Dvoskin S, Halldin MH, Ask AL, Doucette AM.

Reg Anesth. 1997 Sep-Oct;22(5):451-60.

PMID:
9338908
36.

Toxicity of bupivacaine and ropivacaine in relation to free plasma concentrations in pregnant rats: a comparative study.

Danielsson BR, Danielson MK, Böö EL, Arvidsson T, Halldin MM.

Pharmacol Toxicol. 1997 Aug;81(2):90-6.

PMID:
9298506
37.

A GC-MS study of three major acidic metabolites of delta 1-tetrahydrocannabinol.

Szirmai M, Beck O, Stephansson N, Halldin MM.

J Anal Toxicol. 1996 Nov-Dec;20(7):573-8.

PMID:
8934309
38.

Metabolism and excretion of ropivacaine in humans.

Halldin MM, Bredberg E, Angelin B, Arvidsson T, Askemark Y, Elofsson S, Widman M.

Drug Metab Dispos. 1996 Sep;24(9):962-8.

PMID:
8886605
40.
41.
42.

Synthesis of optically active (-)-11-nor-delta 9-tetrahydrocannabinol-9-carboxylic acid.

Baek SH, Szirmai M, Halldin MM.

Pharmacol Biochem Behav. 1991 Nov;40(3):487-9. No abstract available.

PMID:
1666912
43.

Human urinary excretion profile after smoking and oral administration of [14C]delta 1-tetrahydrocannabinol.

Johansson E, Gillespie HK, Halldin MM.

J Anal Toxicol. 1990 May-Jun;14(3):176-80.

PMID:
2165199
44.

Local exhaust ventilation and exposure to nitrous oxide in ambulances.

Ancker K, Göthe CJ, Halldin M.

Int Arch Occup Environ Health. 1990;62(1):27-9.

PMID:
2295520
45.

Disposition kinetics of ropivacaine in humans.

Lee A, Fagan D, Lamont M, Tucker GT, Halldin M, Scott DB.

Anesth Analg. 1989 Dec;69(6):736-8.

PMID:
2589653
46.
47.
48.

Terminal elimination plasma half-life of delta 1-tetrahydrocannabinol (delta 1-THC) in heavy users of marijuana.

Johansson E, Halldin MM, Agurell S, Hollister LE, Gillespie HK.

Eur J Clin Pharmacol. 1989;37(3):273-7.

PMID:
2558889
49.

Determination of delta 1-tetrahydrocannabinol in human fat biopsies from marihuana users by gas chromatography-mass spectrometry.

Johansson E, Norén K, Sjövall J, Halldin MM.

Biomed Chromatogr. 1989 Jan;3(1):35-8.

PMID:
2539872
50.

Prolonged apparent half-life of delta 1-tetrahydrocannabinol in plasma of chronic marijuana users.

Johansson E, Agurell S, Hollister LE, Halldin MM.

J Pharm Pharmacol. 1988 May;40(5):374-5.

PMID:
2899638

Supplemental Content

Loading ...
Support Center